FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  7 8 9 10 11 12 13 14 15 16 17
 
TXT FDA Approves Novo Hemophilia Prophylaxis Drug
01/03/2025
 
 
TXT New Sleep Apnea Indication for Lilly’s Zepbound
01/03/2025
 
 
TXT Astellas Recalls Lots of Prograf and Astagraf
01/03/2025
 
 
TXT FDA Wants Labeling Changes for Buprenorphine
01/03/2025
 
 
TXT Bhargava Phytolab CGMP Violations
01/03/2025
 
 
TXT Global Unique Device ID Database Guidance
01/03/2025
 
 
TXT QS, MDR Violations at Rontis Hellas in Greece
01/03/2025
 
 
TXT FDA Approves BMS’ Opdivo Qvantig Injection
01/03/2025
 
 
TXT FDA Approves Checkpoint’s Unloxcyt
01/03/2025
 
 
TXT FDA Approves Xcovery’s Ensacove for Some Lung Cancers
01/03/2025
 
 
TXT FDA Approves Humacyte’s Symvess
01/03/2025
 
 
TXT Axsome Plans Alzheimer’s NDA on Mixed Data
01/03/2025
 
 
TXT Exclude Liraglutide from Compounding: Novo Nordisk
01/03/2025
 
 
TXT Mylan 6-Item Form FDA-483 Posted
01/03/2025
 
 
TXT FDA Alert on Boston Accolade Pacers Early Replacement
01/03/2025
 
 
TXT CGMP Violations in Micro Orgo Chem Inspection
01/03/2025
 
 
TXT Guide on Drug Batch Uniformity and Integrity
01/03/2025
 
 
TXT Chimerix NDA for Glioma Drug
01/03/2025
 
 
TXT Temple Retires; Bumpus Leaves FDA
01/02/2025
 
 
TXT Xbrane Refiles Lucentis Biosimilar BLA
01/02/2025
 
 
TXT Alert on AquaFlexFlow Blood Circuits
01/02/2025
 
 
TXT Senators Introduce Skinny Label Generic Drug Bill
01/02/2025
 
 
TXT Hologic BioZorb Marker Recall Class 1: FDA
01/02/2025
 
 
TXT UCB Minzasolmin Parkinson’s Study Misses Endpoints
01/02/2025
 
 
TXT FDA Alert on Baxter Solution Sets
01/02/2025
 
 
TXT Lexicon Dropping Zynquista After CRL
01/02/2025
 
 
TXT CRL for Zealand’s SBS Treatment NDA
01/02/2025
 
 
TXT Quality, Data Issues at Mylan Facility in India
01/02/2025
 
 
TXT Boxed Warning for Veozah Liver Injury
01/02/2025
 
 
TXT Sombra Cosmetics CGMP Violations
01/02/2025
 
 
TXT FDA OKs Mesoblast’s Ryoncil Cell Therapy
01/02/2025
 
 
TXT ICH M15 Model-Informed Drug Development Principles
01/02/2025
 
 
TXT AMT Designation Program Guidance
01/02/2025
 
 
TXT ICH E11A Pediatric Extrapolation Guidance
01/02/2025
 
 
TXT ICH Clinical Practice Guide Annex
01/02/2025
 
 
TXT Brands International Limits, Delays Inspection: FDA
01/02/2025
 
 
TXT Multiple Violations in BD Inspection
01/02/2025
 
 
TXT Clinical Investigation Protocol Deviations
01/02/2025
 
 
TXT Updated POLARx Instructions is Class 1 Recall: FDA
01/02/2025
 
 
TXT FDA Seeks Comments on ODAC Briefing Guidance
01/02/2025
 
 
TXT CGMP Violations in Akorn Formulations Review
01/02/2025
 
 
TXT Syndax Leukemia Review Extended by FDA
07/29/2024
 
 
<< Prev  7 8 9 10 11 12 13 14 15 16 17 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving